Cargando…
Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study
BACKGROUND: The Toronto hepatocellular carcinoma (HCC) risk index (THRI) was developed to predict HCC in patients with cirrhosis. This study aimed to validate the THRI in a 10-year Asian cohort. METHODS: A total of 2836 patients with cirrhosis at the First Affiliated Hospital of Soochow University b...
Autores principales: | Zhang, Huixian, Zhu, Jinzhou, Xi, Liting, Xu, Chunfang, Wu, Airong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492382/ https://www.ncbi.nlm.nih.gov/pubmed/31039803 http://dx.doi.org/10.1186/s12957-019-1619-3 |
Ejemplares similares
-
Automated Machine Learning in Predicting 30-Day Mortality in Patients with Non-Cholestatic Cirrhosis
por: Yu, Chenyan, et al.
Publicado: (2022) -
External validation of the Toronto hepatocellular carcinoma risk index in a Swedish population
por: Åström, Hanne, et al.
Publicado: (2021) -
HDL-C levels added to the MELD score improves 30-day mortality prediction in Asian patients with cirrhosis
por: Wang, Yue, et al.
Publicado: (2022) -
Comparative analysis of hepatocellular carcinoma and cirrhosis gene expression profiles
por: Jiang, Mingming, et al.
Publicado: (2017) -
Validation of modified fibrosis-4 index for predicting hepatocellular carcinoma in patients with compensated alcoholic liver cirrhosis
por: Kim, Ji Hyun, et al.
Publicado: (2018)